Neoadjuvant chemo-hormonal therapy before robot-assisted radical prostatectomy resulted in favorable biochemical progression-free survival rates in patients with very high-risk prostate cancer. This result suggests that this therapeutic approach has potential for becoming a new standard of care.
Koyama et al. (Sun,) studied this question.